Cargando…
Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia.
Hypercalcaemia is an important cause of morbidity in malignant disease. We studied the efficacy and safety of intravenous ibandronate (a new, potent bisphosphonate) in a multicentre study of 147 patients with severe cancer-associated hypercalcaemia which had been resistant to treatment with rehydrat...
Autores principales: | Ralston, S. H., Thiébaud, D., Herrmann, Z., Steinhauer, E. U., Thürlimann, B., Walls, J., Lichinitser, M. R., Rizzoll, R., Hagberg, H., Huss, H. J., Tubiana-Hulin, M., Body, J. J. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group|1
1997
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063262/ https://www.ncbi.nlm.nih.gov/pubmed/9010041 |
Ejemplares similares
-
Hypercalcaemia and hypocalcaemia: finding the balance
por: Body, Jean-Jacques, et al.
Publicado: (2017) -
Clinical efficacy and safety of monthly oral ibandronate 100 mg versus monthly intravenous ibandronate 1 mg in Japanese patients with primary osteoporosis
por: Nakamura, T., et al.
Publicado: (2015) -
Treatment of malignant hypercalcaemia with clodronate.
por: Percival, R. C., et al.
Publicado: (1985) -
Hypercalcaemia with Hypocalcuria, an Unusual Case of Primary Hyperparathyroidism
por: Forbes, H. A. W., et al.
Publicado: (1956) -
Clues from hypercalcaemia
por: Nicholson, S, et al.
Publicado: (2002)